Next Article in Journal
Meningitis in a School-Aged Child due to Haemophilus influenzae Type E during the Post-Conjugate Vaccine Era—Monroe County, NY, 2011
Next Article in Special Issue
DNA/MVA Vaccines for HIV/AIDS
Previous Article in Journal
Development of Streptococcus pneumoniae Vaccines Using Live Vectors
Previous Article in Special Issue
Pilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine
Vaccines 2014, 2(1), 89-106; doi:10.3390/vaccines2010089

Recent Developments in Preclinical DNA Vaccination

1,2,3,* , 3
1 Department of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa Prefecture 236-0004, Japan 2 Choju Medical Institute, Toyohashi, Aichi Prefecture 441-8124, Japan 3 Vaccine Institute, Yokohama, Kanagawa Prefecture 2235-0045, Japan
* Author to whom correspondence should be addressed.
Received: 15 October 2013 / Revised: 22 November 2013 / Accepted: 26 November 2013 / Published: 13 January 2014
(This article belongs to the Special Issue DNA Vaccines)
View Full-Text   |   Download PDF [381 KB, uploaded 13 January 2014]


The advantages of genetic immunization of the new vaccine using plasmid DNAs are multifold. For example, it is easy to generate plasmid DNAs, increase their dose during the manufacturing process, and sterilize them. Furthermore, they can be stored for a long period of time upon stabilization, and their protein encoding sequences can be easily modified by employing various DNA-manipulation techniques. Although DNA vaccinations strongly increase Th1-mediated immune responses in animals, several problems persist. One is about their weak immunogenicity in humans. To overcome this problem, various genetic adjuvants, electroporation, and prime-boost methods have been developed preclinically, which are reviewed here.
Keywords: DNA vaccine; genetic adjuvants; electroporation DNA vaccine; genetic adjuvants; electroporation
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Okuda, K.; Wada, Y.; Shimada, M. Recent Developments in Preclinical DNA Vaccination. Vaccines 2014, 2, 89-106.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert